A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels
about
Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistanceFatty acid metabolism and the basis of brown adipose tissue functionModulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acidsTreatment of nonalcoholic fatty liver disease: role of AMPK.Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance.Effect of instant cooked giant embryonic rice on body fat weight and plasma lipid profile in high fat-fed mice.Lower Expression of SLC27A1 Enhances Intramuscular Fat Deposition in Chicken via Down-Regulated Fatty Acid Oxidation Mediated by CPT1A.Mice lacking NKT cells but with a complete complement of CD8+ T-cells are not protected against the metabolic abnormalities of diet-induced obesity.Aqueous extract of post-fermented tea reverts the hepatic steatosis of hyperlipidemia rat by regulating the lipogenic genes expression and hepatic fatty acid compositionMitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model.Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model.Enhancing hepatic mitochondrial fatty acid oxidation stimulates eating in food-deprived mice.Flavonoid ingredients of Ginkgo biloba leaf extract regulate lipid metabolism through Sp1-mediated carnitine palmitoyltranferase 1A up-regulationChronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice.Hepatic Steatosis as a Marker of Metabolic Dysfunction.Developmental bisphenol A (BPA) exposure leads to sex-specific modification of hepatic gene expression and epigenome at birth that may exacerbate high-fat diet-induced hepatic steatosis.Carnitine Palmitoyltransferase 1 Increases Lipolysis, UCP1 Protein Expression and Mitochondrial Activity in Brown Adipocytes.Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liverPGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion.Comparative effects of doenjang prepared from soybean and brown rice on the body weight and lipid metabolism in high fat-fed mice.Impact of maternal undernutrition around the time of conception on factors regulating hepatic lipid metabolism and microRNAs in singleton and twin fetusesHydroxypropyl methylcellulose, a viscous soluble fiber, reduces insulin resistance and decreases fatty liver in Zucker Diabetic Fatty rats.Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implicationsNaringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.Similar degrees of obesity induced by diet or aging cause strikingly different immunologic and metabolic outcomesThe presence of the ovary prevents hepatic mitochondrial oxidative stress in young and aged female mice through glutathione peroxidase 1CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.Chinese medicine formula lingguizhugan decoction improves Beta-oxidation and metabolism of Fatty Acid in high-fat-diet-induced rat model of Fatty liver disease.The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding.Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null miceHepatic fatty acid trafficking: multiple forks in the roadTiming and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny.Mitochondrial dysfunction in nonalcoholic steatohepatitis.Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors.Steatosis in the liver.Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot?Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization.Binge ethanol-induced HDAC3 down-regulates Cpt1α expression leading to hepatic steatosis and injury.
P2860
Q24648189-0E69E8AA-CFD3-408A-84A2-4E3661D530EDQ26744147-CCE1679A-0694-48A7-B39C-FDBCCDBE5054Q28573526-C5C661F2-AFB5-4280-B574-C543F4B5DBB8Q30248230-445A146E-6A32-492E-8112-96A0E5925692Q33604466-3594C3CF-DD19-429D-BAFB-DA53ABF9CAE7Q33813709-844601D3-AC84-4A50-AF65-69D4BEE8A863Q33849841-4D6300A1-6D01-4FC1-AA45-D9DC7E419825Q33933019-E84D23C1-0131-4112-A99B-A577E55BD346Q34006718-2C67F035-AC48-492B-BD80-3459660BA9B9Q34021867-09A341CF-839A-4972-8464-793488112B6DQ34053063-8F8E2F4A-76ED-4E16-8FB9-1280CE53D590Q34412650-0303EC2C-CFEC-490E-A685-C3B4DF500CF8Q34979962-20675384-C630-4B6B-87DA-6449C36A8660Q34980719-56EB2896-61BC-4DA5-982B-1B05EA98E8ECQ35596837-3D11BDDC-B396-422F-9787-6558722ABD3FQ35605858-7F7D568E-28FE-4B2D-8F8E-34E26DB4D146Q35809069-809797E4-5731-42F9-B0FE-1999807494C6Q35903462-534A3365-BEA9-409E-A77A-9F018F374D43Q36082820-8D648A1A-E078-4A96-B5BC-9272562C831FQ36182556-5D2872C4-192E-47DD-86B4-AA6A2BCA4CFEQ36312713-91EA5C10-AC6E-42C5-9C87-E50A4BA38866Q36377652-0DFA7347-A1AA-4212-9BF4-8CFAF671FD46Q36480300-E5AD0007-8A00-4541-BD6A-5C81DF0E5D19Q36591525-13AA9218-D79C-4985-8339-85019B577EEAQ36617551-7E579D7E-000E-4591-A946-09FDD03E1628Q36744105-09306634-F0CC-454F-84C3-57C182D750B8Q36748304-16382631-89B9-46CA-95AA-1708B6264DD9Q36776359-BC939721-1566-45C8-B771-EAC236ECC5F9Q36867088-425A8FE5-C6AB-4DC9-93A3-89BBB5A244C3Q36879157-30C859FD-6F05-4FF4-9C1B-B7DE014E9A57Q36922115-4A10E2F1-CA38-489D-873C-89596986E3A3Q37267076-0CA998D5-1385-4B89-8080-728B3041124EQ37296476-E88EC36D-9B83-4106-80FD-057435F16FFCQ37666701-32B0F0C8-B8D0-4DC8-9DC7-F2096DC434D6Q37863137-DAC822E5-99B8-489B-A770-392EB08B8C61Q38062510-6BFE7D0D-1D61-47DD-AB56-6A8A5BA298E4Q38165140-7CCDF4B8-5226-4852-9DD6-632F59BD3DCEQ38287064-78964D3E-BE31-4C4B-AA45-A71D0397ED78Q38555120-3954013F-5486-4CB6-84C8-0A2381954059Q38617340-DE312C54-AD01-4C7C-9894-C585C4D3CF5F
P2860
A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels
description
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
scientific journal article
@en
vedecký článok (publikovaný 2008/05/01)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/05/01)
@nl
наукова стаття, опублікована в травні 2008
@uk
مقالة علمية (نشرت في مايو 2008)
@ar
name
A moderate increase in carniti ...... ce hepatic triglyceride levels
@ast
A moderate increase in carniti ...... ce hepatic triglyceride levels
@en
A moderate increase in carniti ...... ce hepatic triglyceride levels
@nl
type
label
A moderate increase in carniti ...... ce hepatic triglyceride levels
@ast
A moderate increase in carniti ...... ce hepatic triglyceride levels
@en
A moderate increase in carniti ...... ce hepatic triglyceride levels
@nl
prefLabel
A moderate increase in carniti ...... ce hepatic triglyceride levels
@ast
A moderate increase in carniti ...... ce hepatic triglyceride levels
@en
A moderate increase in carniti ...... ce hepatic triglyceride levels
@nl
P2093
P3181
P1476
A moderate increase in carniti ...... ce hepatic triglyceride levels
@en
P2093
Ian J Sipula
Maja Stefanovic-Racic
Nicholas F Brown
Robert M O'Doherty
P304
P3181
P356
10.1152/AJPENDO.00497.2007
P577
2008-03-18T00:00:00Z